SGR-1505
Phase 1Small molecule
SGR-1505 is one of 9 small molecule programs targeting B-cell neoplasm. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in B-Cell Neoplasm
#DrugCompanyPhaseTrials
1Epkinly
GenmabPhase 1
Velcade
SShilpa Grover, MD, MPH
Phase 1
PCI 32765
Johnson & JohnsonPhase 1
Zamtocabtagene Autoleucel
MMiltenyi Biomedicine GmbH
Phase 2
Polivy
RochePreclinical
HMPL-523
HHutchison Medipharma Limited
Phase 1
Zynlonta
Akero TherapeuticsPreclinical
Alvocidib Hydrochloride
NNational Cancer Institute (NCI)
Phase 1
SGR-1505
SSchrödinger, Inc.
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SGR-1505. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSchrödinger, Inc.